出版：Market Research Future（マーケットリサーチフューチャー） 出版年月：2021年08月
再生医療市場：タイプ（細胞治療、遺伝子治療、組織工学、小分子、生物学的）、材料（合成、遺伝子操作、生物学的派生）、用途（筋骨格障害、創傷ケア、腫瘍学、眼障害、糖尿病）、エンドユーザー（病院、専門センター、学術研究機関）、地域（アメリカ、ヨーロッパ、アジア太平洋、中東、アフリカ）- 2027年までの予測
Regenerative Medicine Market: Information by Type (Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecule & Biologic), by Material (Synthetic, Genetically Engineered, Biologically Derived), by Application (Musculoskeletal Disorders, Wound Care, Oncology,Ocular Disorders,Diabetes), by End User (Hospitals, Specialty Centers, Academic & Research Institutes), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027
| ページ数 | 171 |
| 価格 | |
| シングルユーザライセンス | USD4,450 |
| エンタープライズライセンス | USD6,250 |
| 種別 | 英文調査報告書 |
Regenerative Medicine Market—Forecast till 2027
Market Review
The regenerative medicine market is evaluated to register a substantial CAGR of 21.18% during the projected timeframe to surpass USD 152,501.51 million by 2027. Regenerative medicine is the part of medicine that creates techniques to regrow, fix or supplant harmed or unhealthy cells, organs, or tissues. Regenerative medicine incorporates the age and utilization of helpful undifferentiated cells, tissue designing, and the creation of dummy organs.
The worldwide regenerative medicine market is developing quickly and is anticipated to keep developing at a consistent rate during the review time frame. This is because of the developing commitment of existing players to make the item more viable. The inventory network investigation for the regenerative medicine market contains four significant parts, which start with the examination and item advancement followed by assembling of the items, conveyance, and deals, and finishes with post-deals administrations. Variables that impact the regenerative medicine market are expanding headway in medical services innovation, cutting edge innovation in the regenerative medicine market, expanding pervasiveness of constant infections, and expanding development in foundational microorganism innovation.
Segment Overview
The global regenerative medicine market has been divided based on type, material, application, and end-user. In terms of material type the global market has been classified into synthetic, genetically engineered, biologically derived, and others.
By Type, the global market has been dispersed into cell therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic. The application segment categorizes the global market as musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and others.
In terms of end-user, the regenerative medicines market is divided into hospitals, specialty centers, academic & research institutes, and others.
Regional Analysis
The region-specific analysis of the global regenerative medicine market has been classified into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to drive the largest market of the global regenerative medicines market during the review period. the regional market is attributed to the favorable government policies, and establishment of institutions such as the American Academy of Regenerative Medicine (AARM) and the American Board of Regenerative Medicine (ABRM), rising monetary support by investors. Europe additionally represented a huge portion of the overall industry attributable to the accomplishment of the skillet European undertakings (like CHRODIS and CHRODIS PLUS), government drives, public and private examination funders, and community-oriented logical exploration projects in the field of regenerative medicine.
Asia-Pacific is assessed to be huge in regenerative medicine treatment because of changes in medical care foundation, cross-country logical exploration projects, and preparing of scientists and youthful resources at driving establishments in the field of tissue designing and undifferentiated organism-based examination.
Major Players
The major players of the global regenerative market include Zimmer Biomet Holdings Inc. (US), AbbVie Inc. (US), Cryolife, Inc. (US), Stryker (US), Medtronic Plc (Ireland), Baxter International Inc. (US), Organogenesis Inc. (US), Ocata Therapeutics Inc. (US), Integra Lifesciences Holdings Corporation (US), Vericel Corporation (US), and Reliance Life Sciences (India)
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS
4.2.2 GROWING ADOPTION OF STEM CELL TECHNOLOGY
4.2.3 RISING PRODUCT PIPELINE OF REGENERATIVE MEDICINE
4.3 RESTRAINT
4.3.1 ETHICAL CONCERNS FOR THE USE OF EMBRYONIC STEM CELLS
4.4 OPPORTUNITY
4.4.1 IMPLICIT GUIDELINES BY THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) RELATED TO THE EXTENDED EMBRYO CULTURE
4.5 COVID-19 IMPACT ANALYSIS
4.5.1 IMPACT ON MARKET PLAYERS
4.5.2 BRANDED AND GENERIC DRUGS IMPACT ANALYSIS
4.5.3 R&D IMPACT ANALYSIS
4.5.4 FDA POLICIES
4.5.5 OPPORTUNITY ANALYSIS
4.6 PIPELINE ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION AND SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
6 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE
6.1 OVERVIEW
6.2 CELL THERAPY
6.3 GENE THERAPY
6.4 TISSUE ENGINEERING
6.5 SMALL MOLECULE & BIOLOGIC
7 GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL
7.1 OVERVIEW
7.2 SYNTHETIC
7.3 GENETICALLY ENGINEERED
7.4 BIOLOGICALLY DERIVED
7.5 OTHERS
8 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 MUSCULOSKELETAL DISORDERS
8.3 WOUND CARE
8.4 ONCOLOGY
8.5 OCULAR DISORDERS
8.6 DIABETES
8.7 OTHERS
9 GLOBAL REGENERATIVE MEDICINE MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CENTERS
9.4 ACADEMIC & RESEARCH INSTITUTES
9.5 OTHERS
10 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 U.S
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 COMPETITIVEOVERVIEW
11.2 COMPETITOR DASHBOARD
11.3 MAJOR PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL REGENERATIVE MEDICINE MARKET
11.5 COMPETITIVE BENCHMARKING
11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.7.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES
11.7.2 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
11.8.1 SALES & OPERATING INCOME
11.8.2 R&D EXPENDITURE
12 COMPANY PROFILES
12.1 ZIMMER BIOMET HOLDINGS INC.
12.1.1 COMPANY OVERVIEWS
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 ABBVIE INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 CRYOLIFE, INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 STRYKER
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 MEDTRONIC PLC
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 BAXTER INTERNATIONAL INC.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 ORGANOGENESIS INC.
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 OCATA THERAPEUTICS INC.
12.8.1 COMPANY OVERVIEW
12.8.4 KEY DEVELOPMENTS
12.9 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 VERICEL CORPORATION
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
12.11 RELIANCE LIFE SCIENCES
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 SWOT ANALYSIS
12.11.6 KEY STRATEGIES
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PIPELINE ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET
TABLE 3 GLOBAL: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 4 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR CELL THERAPY, BY REGION, 2017–2027 (USD MILLION)
TABLE 5 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 6 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR GENE THERAPY, BY REGION, 2017–2027 (USD MILLION)
TABLE 7 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR TISSUE ENGINEERING, BY REGION, 2017–2027 (USD MILLION)
TABLE 8 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR SMALL MOLECULE & BIOLOGIC, BY REGION, 2017–2027 (USD MILLION)
TABLE 9 GLOBAL: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 10 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR SYNTHETIC, BY REGION, 2017–2027 (USD MILLION)
TABLE 11 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR GENETICALLY ENGINEERED, BY REGION, 2017–2027 (USD MILLION)
TABLE 12 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR BIOLOGICALLY DERIVED, BY REGION, 2017–2027 (USD MILLION)
TABLE 13 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 14 GLOBAL: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 15 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 16 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR WOUND CARE, BY REGION, 2017–2027 (USD MILLION)
TABLE 17 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR ONCOLOGY, BY REGION, 2017–2027 (USD MILLION)
TABLE 18 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OCULAR DISORDERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 19 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR DIABETES, BY REGION, 2017–2027 (USD MILLION)
TABLE 20 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 21 GLOBAL: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 22 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR HOSPITALS, BY REGION, 2017–2027 (USD MILLION)
TABLE 23 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR SPECIALTY CENTERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 24 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017–2027 (USD MILLION)
TABLE 25 GLOBAL: REGENERATIVE MEDICINE MARKET, FOR OTHERS, BY REGION, 2017–2027 (USD MILLION)
TABLE 26 GLOBAL: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 27 AMERICAS: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 28 AMERICAS: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 29 AMERICAS: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 30 AMERICAS: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 31 AMERICAS: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 32 AMERICAS: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 33 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 39 US: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 40 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 41 US: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 42 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 43 US: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 44 CANADA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 45 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 46 CANADA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 47 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 48 CANADA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 49 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 50 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 51 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 52 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 53 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 55 EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 56 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 57 EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 58 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 60 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017–2027 (USD MILLION)
TABLE 61 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 62 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 63 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 64 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 65 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 66 GERMANY: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 67 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 68 GERMANY: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 69 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 70 GERMANY: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 71 FRANCE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 72 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 73 FRANCE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 74 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 75 FRANCE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 76 UK: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 77 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 78 UK: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 79 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 80 UK: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 81 ITALY: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 82 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 83 ITALY: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 84 ITALY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 85 ITALY: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 86 SPAIN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 87 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 88 SPAIN: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 89 SPAIN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 90 SPAIN: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 91 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 92 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 93 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 94 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 95 REST OF WESTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 96 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 97 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 98 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 99 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 100 EASTERN EUROPE: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 101 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2017–2027 (USD MILLION)
TABLE 102 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 105 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 107 CHINA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 108 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 109 CHINA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 110 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 111 CHINA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 112 INDIA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 113 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 114 INDIA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 115 INDIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 116 INDIA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 117 JAPAN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 118 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 119 JAPAN: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 120 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 121 JAPAN: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 122 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 123 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 124 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 125 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 126 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 127 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 128 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 129 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 130 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 131 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 132 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 133 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 134 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 135 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 136 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2027 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 139 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 140 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 141 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 143 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 144 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 145 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 146 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 147 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 148 AFRICA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2027 (USD MILLION)
TABLE 149 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2017–2027 (USD MILLION)
TABLE 150 AFRICA: REGENERATIVE MEDICINE MARKET, BY MATERIAL, 2017–2027 (USD MILLION)
TABLE 151 AFRICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2027 (USD MILLION)
TABLE 152 AFRICA: REGENERATIVE MEDICINE MARKET, BY END USER, 2017–2027 (USD MILLION)
TABLE 153 MAJOR PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
TABLE 154 THE MOST ACTIVE PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
TABLE 155 NEW PRODUCT DEVELOPMENTS/LAUNCHES
TABLE 156 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/JOINT VENTURES
TABLE 157 MAJOR PLAYERS R&D EXPENDITURE 2020
TABLE 158 ZIMMER BIOMET HOLDINGS INC.: PRODUCTS/SERVICES OFFERED
TABLE 159 ZIMMER BIOMET HOLDINGS INC.: KEY DEVELOPMENTS
TABLE 160 ABBVIE INC.: PRODUCTS/SERVICES OFFERED
TABLE 161 ABBVIE INC.: KEY DEVELOPMENTS
TABLE 162 CRYOLIFE, INC.: PRODUCTS/SERVICES OFFERED
TABLE 163 STRYKER: PRODUCTS/SERVICES OFFERED
TABLE 164 STRYKER: KEY DEVELOPMENTS
TABLE 165 MEDTRONIC PLC: PRODUCTS/SERVICES OFFERED
TABLE 166 BAXTER INTERNATIONAL INC.: PRODUCTS OFFERED
TABLE 167 ORGANOGENESIS INC.: PRODUCTS/SERVICES OFFERED
TABLE 168 ORGANOGENESIS INC.: KEY DEVELOPMENTS
TABLE 169 OCATA THERAPEUTICS INC.: PRODUCTS/SERVICES OFFERED
TABLE 170 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 171 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY DEVELOPMENTS
TABLE 172 VERICEL CORPORATION: PRODUCTS OFFERED
TABLE 173 VERICEL CORPORATION: KEY DEVELOPMENTS
TABLE 174 RELIANCE LIFE SCIENCES: PRODUCTS/SERVICES OFFERED
LIST OF FIGURES
FIGURE 1 GLOBAL REGENERATIVE MEDICINE MARKET STRUCTURE
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 3 MARKET DYNAMICS: REGENERATIVE MEDICINE MARKET
FIGURE 4 DRIVERS: IMPACT ANALYSIS
FIGURE 5 RESTRAINT: IMPACT ANALYSIS
FIGURE 6 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
FIGURE 7 PORTER’S FIVE FORCES ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET
FIGURE 8 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE, 2020 & 2027 (USD MILLION)
FIGURE 9 GLOBAL: REGENERATIVE MEDICINE MARKET, MATERIAL 2020 & 2027 (USD MILLION)
FIGURE 10 GLOBAL: REGENERATIVE MEDICINE MARKET, APPLICATION, 2020 & 2027 (USD MILLION)
FIGURE 11 GLOBAL: REGENERATIVE MEDICINE MARKET, END USER, 2020 & 2027 (USD MILLION)
FIGURE 12 GLOBAL: REGENERATIVE MEDICINE MARKET, BY REGION 2020 & 2027 (USD MILLION)
FIGURE 13 GLOBAL: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)
FIGURE 14 AMERICAS: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)
FIGURE 15 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SHARE, BY COUNTRY 2020 (%)
FIGURE 16 EUROPE: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)
FIGURE 17 WESTERN EUROPE: REGENERATIVE MEDICINE MARKET SHARE, BY COUNTRY 2020 (%)
FIGURE 18 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SHARE, BY COUNTRY 2020 (%)
FIGURE 19 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET SHARE, BY REGION 2020 (%)
FIGURE 20 COMPETITOR DASHBOARD: GLOBAL REGENERATIVE MEDICINE MARKET
FIGURE 21 CONTRACTS & AGREEMENTS: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET
FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 23 SALES & OPERATING INCOME 2020
FIGURE 24 ZIMMER BIOMET HOLDINGS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 ZIMMER BIOMET HOLDINGS INC.: SWOT ANALYSIS
FIGURE 26 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 ABBVIE INC.: SWOT ANALYSIS
FIGURE 28 CRYOLIFE, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 CRYOLIFE, INC.: SWOT ANALYSIS
FIGURE 30 STRYKER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 STRYKER: SWOT ANALYSIS
FIGURE 32 MEDTRONIC PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 MEDTRONIC PLC: SWOT ANALYSIS
FIGURE 34 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS
FIGURE 36 ORGANOGENESIS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 ORGANOGENESIS INC.: SWOT ANALYSIS
FIGURE 39 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: SWOT ANALYSIS
FIGURE 41 VERICEL CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 VERICEL CORPORATION: SWOT ANALYSIS
FIGURE 43 RELIANCE INDUSTRIES LIMITED: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 RELIANCE LIFE SCIENCES: SWOT ANALYSIS